Fewer than 10% of people who could benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it issues its inaugural guidance on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs.
According to forecasts, more than two billion could be obese by 2030 without intervention.
"The new guidelines recognises that excess weight is a long-term condition that can be addressed with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major barriers to broad access to the injections that can help people shift considerable body mass, says the body.
Skinny Jab Supply Crisis
Despite the current most optimistic scenario, the supply of these medications could only cover about 100 million people – under 10% of those who need them, according to the health organization.
The guideline encourages governments and firms to expand access, via measures like voluntary licensing.
The intellectual property rights on semaglutide – the primary component of a leading brand – is due to expire in a number of countries in 2026.
How Weight-Loss Injections Function
GLP-1 drugs replicate a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so individuals eat less.
Patients typically see weight reduction after several weeks of commencing the regular doses.
Studies points to people may regain a significant portion a year later of halting the medication, because their usual hunger return.
To be overweight or obese increases your risk for experiencing medical conditions, like diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
